

Research Journal of Chemical Sciences _ Vol. 6(1), 61-68, January (2016)

Synthesis and Biological activities of 1,2-Benzisoxazoles and their N-Glucosides

Yogesh V. Punatkar¹, Rajendra K. Wanare² and Ravin M. Jugade¹*

¹Department of Chemistry, Mahatma Jyotiba Phule, Educational Campus, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur-440 033,

INDIA

²Department of Chemistry, Jawaharlal Nehru College, Wadi, Nagpur-440 023, INDIA

ravinj2001@yahoo.co.in

Available online at: www.isca.in, www.isca.me

Received 30th Augustr 2015, revised 24th September 2015, accepted 12th November 2015

Abstract

2-oximinoacetyl-4-acetyl phenol 2 was prepared by the interaction of 2,4-diacetyl phenol 1 with hydroxylamine hydrochloride using suitable solvent. Cyclization of product 2 with acetic anhydride using N,N-Dimethylformamide afforded 3-methyl-5-acetyl-1,2-benzisoxazole 3. Nitration of compound 3 with nitrating mixture produces 3-methyl-5-acetyl-7-nitro-1,2-benzisoxazole 4. 3-Methyl-5-acetyl-7-amine-1,2-benzisoxazole 5 was prepared by the reduction of product 4 using tin and hydrochloric acid. Different 3-methyl-5-(3'-aryl prop-2'-enoyl)-7-amine-1,2-benzisoxazoles 6a-j have been synthesized by the interaction of appropriate 3-methyl-5-(acetyl-7-amine-1,2-benzisoxazole 5 with different aromatic aldehydes using piperidine. The reaction of 3-methyl-5-(3'-aryl prop-2'-enoyl)-7-amine-1,2-benzisoxazoles 6a-j with hydrazine hydrate in alcoholic KOH to obtained 3-methyl-5-(3'-aryl prop-2'-enoyl)-7-amine-1,2-benzisoxazoles 7a-j. Condensation of tetra-0-acetyl- α -D-glucopyranosyl bromide with compounds 7a-j furnishes 3-methyl-5-(3'-aryl-1H-pyrazol-5'-yl)-7-amine-(β -D-glucopyranosyl)-1,2-benzisoxazoles 8a-j which on deprotection to get 3-methyl-5-(3'-aryl-1H- pyrazol-5'-yl)-7-amine-(β -D-glucopyranosyl)-1,2-benzisoxazoles 9a-j. The synthesized compounds were characterized on the basis of IR, ¹H NMR, ¹³C NMR and Mass Spectroscopy, Elemental analysis, TLC, chemical properties and Polarographic studies. All

Keywords: 1,2-Benzisoxazole, Amino compounds, Pyrazoles, N-Glucosides and Polarography.

Introduction

Heterocyclic chemistry is a vast and expanding area of chemistry because of the obvious applications of compounds derived from heterocyclic rings in pharmacy, medicine, agriculture and other fields. The chemistry of heterocyclic compounds is as relevant as that of alicyclic or aromatic compounds. Heterocyclic compounds used as pharmaceuticals, agrochemicals and veterinary products, used as optical brightening agents, as antioxidants, as corrosion inhibitors and as additives with a variety of other functions¹. Also, many dyestuffs and pigments have heterocyclic structures². A heterocyclic compounds such as isoxazole, pyrazoles, furans, pyrroles. thiazines. oxazines etc. exhibit diverse pharmacological activities such as potential anti-fungal agents, anti-bacterial agents, antiviral, anti-inflammatory, herbicidal, anticancer, cytotoxic, anaesthetics, insecticidal³⁻¹¹ etc. The term pyrazole refers to the class of simple aromatic ring organic compounds of the heterocyclic series. The first natural pyrazole, 1-pyrazolyl-alanine, was isolated from seeds of watermelons¹² in 1959. Pyrazole derivatives show application in agrochemicals as herbicides and in pharmaceutical industry as active pharmaceuticals; the COX-2 inhibitor has further highlighted the importance of these heterocyclic rings in medicinal chemistry. Many pyrazoles are used for the treatment of thyroid

and leukaemia having possessed wide range of pharmacological activities like antioxidant, antipyretic, anti-invasive, antiviral, anti-inflammatory, anti-depressant, agrochemicals, and dyestuffs in sunscreen materials etc¹³. The derivatives of 1,3,4-oxidiazole possess antibacterial, fungitoxic, insecticidal, herbicidal and anticancer¹⁴⁻¹⁸. Cocconcelli, et al, reported aryl azoles shows neuroprotective activity¹⁹.

Benzisoxazoles have recently attracted attention as an important class of heterocyclic compounds in the field of drugs and pharmaceuticals. These compounds are widely used as analgesic, anticonvulsant, antipsychotic and antimicrobial²⁰⁻²¹ agents. They are present in large number of pharmaceutical important products with antitumor, antithrombotic and cholinesterase-inhibiting properties²²⁻²³. 1,2-Benzisoxazoles derivatives have been found to possess antidepressant and hypotensive activity²⁴, as potent and selective inhibitors of the enzyme acetyl cholinesterase²⁵, evaluated as a potential antipsychotic D2/5-HT2 antagonists²⁶. Two patents have claimed that substituted 3-(aminoalkylamino)-1.2benzisoxazoles are useful for the treatment of various memory dysfunctions and as antidepressants by inhibiting monoamine oxidase²⁷. 6-fluro-4-piperidinyl-1,2-benzisoxazole-amides were synthesized and tested against antimicrobial agents and reported potent inhibition against antimicrobial stains²⁸.

Heterocyclic substituted chalcones were prepared by Bombardeli and Valenti reported some of them were introduced for the treatment of breast cancer, menopausal disorders and osteoporosis²⁹.

Chalcone derivatives have found a wide range of application in the pharmacological activities such as potential cytotoxic properties are reported by Bhatt, et al.³⁰, antiviral, anaesthetics, mydriatics, antimicrobial, anti-mitotic, antitumor, cytotoxicity, antipyretic, antifungal, anti-inflammatory, insecticidal and anti-HIV properties³¹⁻³⁵. Venkatachalam et al. reported anti-oxidant activity of substituted chalcone³⁶.

Glucosylation improves the solubility of various drugs without affecting their activities and attaching of the glucosidic moiety into the molecules increases its hydrophilicity than the respective aglycon. β -Glucosylation can improve the drug targeting to the cells due to their solubility in the membrane components³⁷. The carbohydrate moiety enhances the water and lipid solubility of the pharmacophoric group and the major active molecule is the aglycone which is responsible for its biological activities³⁸. The screening results indicate that glucosides showed moderate to excellent antibacterial activity against *E. coli* and *S. aureus* organisms as compared to aglycon³⁹⁻⁴⁰.

In the view of pronounced biological and pharmacological applications of Chalcones, 1,2-Benzisoxazoles, Nitro, Amine derivatives, Pyrazoles and *N*-Glucosides. It was planned to synthesize new chemical entities having active pharmacological functions namely chalcones, benzisoxazoles, nitro, amine, pyrazoles and their *N*-glucosides moiety in a single molecular framework as a new biological active compounds.

Materials and Methods

Melting points were determined on a melting point apparatus in open capillaries and are uncorrected. IR spectra were recorded on Bruker infrared spectrometer, ¹H NMR, ¹³C NMR spectra on Bruker Avance II 400 NMR spectrometer and MS spectra were recorded and polarograms were recorded on Elico CL-362 polarograph.

General Synthesis: Synthesis of 2,4-diacetyl phenol (1). It is prepared by Fries rearrangement reaction as reported in literature. The crude product 2,4-diacetyl phenol was crystallized from aqueous alcohol, decolourised with activated charcoal powder and pure colourless crystalline solid product was obtained. Yield 14.5g, 81.4%, MP 97°C and its alcoholic solution gave violet colour with neutral FeCl₃ solution.

IR: v_{max} cm⁻¹:3353(br. OH peak), 2868-2972 (C-H str. In benzene), 1641 & 1670 (C=O two), 1489 (C=C str. in benzene); ¹H-NMR: δ 12.69 (s, 1H, OH), δ 8.44 (d, *J*=2.04 Hz, 1H, Ar-H), δ 8.05-8.08 (m, 1H, Ar-H), δ 7.04 (d, *J*=8.76 Hz, Ar-H), δ 2.72 (s, 3H, CH), δ 2.59 (s, 3H, CH); ¹³C-NMR: δ 204.85 (C=O), δ 195.84

(C=O), $\delta 166.07$ (C-1), $\delta 136.37$ (C-5), $\delta 131.87$ (C-4), $\delta 130.86$ (C-3), $\delta 119.22$ (C-2), $\delta 115.37$ (C-1), $\delta 26.76$ (CH₃), $\delta 26.32$ (CH₃); MS: m/z 179, 164, 161, 137.

Synthesis of 2-oximinoacetyl-4-acetyl phenol (2): A mixture of 2,4-diacetyl phenol (17.8g, 0.1M), hydroxylamine hydrochloride (6.9g, 0.1M), sodium acetate (8.2g, 0.1M) and 50mL of EtOH/H₂O (7:3) was refluxed for 2hrs. After cooling colourless solid were filtered, washed with water, dried and crystallised by aq. alcohol. (Yield 16.2g, 83.93%), MP 174°C and its alcoholic solution gave violet colour with neutral FeCl₃ solution.

Synthesis of 3-methyl-5-acetyl-1,2-Benzisoxazole (3): To a solution of 2-oximinoacetyl-4-acetyl phenol (19.3g, 0.1M) and *N*,*N*-dimethylformamide (8.0mL), sodium acetate (18.0g, 0.22M) and acetic anhydride (21.8mL, 0.23M) were added, the reaction mixture was refluxed for 4hr at which state all the starting material was consumed as indicated by TLC. After cooling the reaction mixture was poured into ice cold water. A brownish solid was filtered and dried. (Yield 13.1g, 74.81%), MP 112°C and its alcoholic solution gave no violet colour with neutral FeCl₃ solution.

IR: v_{max} cm⁻¹:2862-3057 (C-H str. In benzene), 1633 (C=O), 1467 (C=C str. in benzene). ¹H-NMR: δ 8.03 (d, *J*=1.08 Hz, 1H, Ar-H), δ 7.96-7.99 (m, 1H, Ar-H), δ 7.57 (d, *J*=8.84 Hz, 1H, Ar-H), δ 2.69 (s, 3H, CH₃), δ 2.47 (s, 3H, CH₃); ¹³C-NMR: δ 194.15 (C=O), δ 168.66 (C-8), δ 155.50 (C-3), δ 130.56 (C-5), δ 128.83 (C-6), δ 122.70 (C-4), δ 120.83 (C-9), δ 110.10 (C-7), δ 24.79 (CH₃), δ 14.77 (CH₃).

Synthesis of 3-methyl-5-acetyl-7-nitro-1,2-benzisoxazole (4): Nitration of 3-methyl-5-acetyl-1,2-benzisoxazole (17.5g, 0.1M) in nitrating mixture [conc. H_2SO_4 (30mL) and conc. HNO_3 (7mL)]. After addition was complete, the reaction mixture was warmed to room temperature and stirred. After the starting material was consumed as indicated by TLC the reaction mixture was poured slowly on ice with constant shaking. The resulting yellow solid was filtered and dried. Yield 20.40g, 86.44%, MP 66°C.

Synthesis of 3-methyl-5-acetyl-7-amine-1,2-benzisoxazole (5): The appropriate 3-methyl-5-acetyl-7-nitro-1,2-benzisoxazole (23.6g, 0.1M) and tin granules (35.6g, 0.3M) were thoroughly ground together and then concentrated HCl (100 mL) was added slowly with vigorous stirring. After the addition of acid the reaction mixture was boiled for 30 min. and then allowed to cool to room temperature. The solution was diluted with water (50mL) cooled in an ice bath and made alkaline with 20 % NaOH solution added over 5-10 min. The resulting precipitate was filtered, washed with 2M NaOH and then water. (Yield 12.3g, 64.73%), MP 136°C and functional group test i.e. Dye test was positive.

IR: v_{max}cm⁻¹: 3323 (-NH₂), 3261 (-NH₂), 2885-3054 (C-H str. In

benzene), 1637 (C=O), 1568 (C=N), 1615 (bend N-H); $^1\mathrm{H-NMR}$: $\delta 8.36\text{-}8.39$ (t, 1H, Ar-H), $\delta 8.11\text{-}8.18$ (t, 1H, Ar-H), $\delta 4.24$ (s, 2H, NH_2), $\delta 2.67$ (s, 3H, CH_3), $\delta 2.56$ (s, 3H, CH_3); MS: m/z 190, 178 , 173, 162, 160, 134, 131.

Synthesis of 3-methyl-5-(3-phenyl prop-2-enoyl)-7-amine-1,2-benzisoxazole (6a). Condensation of 3-methyl-5-acetyl-7amine-1,2-benzisoxazole (1.90g, 0.01M) with benzaldehyde (1.0 mL, 0.01M) in ethyl alcohol (25 mL) using a few drops of piperidine for 40 min. The reaction mixture was cooled to 0°C, yellow solid compound formed was washed with water. (Yield 2.10g, 75.50%), MP 92°C and its alcoholic solution turned red with alkali and decolourised with bromine water and it gave dark red colour with conc. H_2SO_4 .

IR: v_{max} cm⁻¹: 3359 (-NH₂), 3253 (-NH₂), 2840-3067 (C-H str. In benzene), 1734 (C=O). ¹H-NMR: δ8.79, (d, *J*=5.96, 1H, C=O-C-H=C-H), δ8.47, (t, 1H, C=O-C-H=C-H), δ8.21 (d, *J*=8.08 Hz, 1H, Ar-H), δ8.07 (d, *J*=9.84 Hz, 1H, Ar-H), δ7.45-7.82 (m, 4H, Ar-H), δ7.03 (d, *J*=11.12 Hz,1H, Ar-H), δ4.22 (s, 2H, NH₂), δ2.69 (s, 3H, CH₃); ¹³C-NMR: δ198.31 (C=O), δ160.61 (C-8), δ150.69 (C-9), δ141.79 (ethylene CH), δ139.32 (C-1'), δ136.06(C-5), δ133.96 (C-7), δ131.80 (C-3'), δ129.27 (C-5'), δ127.39 (C-4'), δ126.97 (C-2'), δ125.98(C-6'), δ125.18 (C-9), δ123.09 (ethylene CH), δ119.03 (C-6), δ114.43 (C-4), δ14.78 (CH₃); MS: m/z 279, 262, 247, 184, 179, 164, 160, 136.

In the same way, other chalcones 3-methyl-5-(3-aryl prop-2enoyl)-7-amine-1,2-benzisoxazoles (**6b-j**) were prepared.

Synthesis of 3-methyl-5-(3-phenyl-1*H*-pyrazol-5-yl)-7-amine-1,2-benzisoxazole (7a). A mixture of 3-methyl-5-(3-phenyl prop-2-enoyl)-7-amine-1,2-benzisoxazole (2.78g, 0.01M), hydrazine hydrate (0.5g), ethyl alcohol (15mL) and KOH (0.4g) was refluxed on water bath for 4hours. It was cooled and acidified with glacial acetic acid (1.5mL) and was poured on ice-cold water (50mL), dried and crystallised with aqueous alcohol. Yield 63%, MP 126°C. It did not give dark red colour with conc. H_2SO_4 .

IR: υ_{max} cm⁻¹: 3243 (-NH₂), 3198 (-NH₂), 3064-2839 (C-H str. In benzene), 1693 (C=N). ¹H-NMR: $\delta 8.36-6.87(7 \text{ H}, \text{Ar-H}), \delta 6.98$ (s, 1H, Pyrazole), $\delta 11.69$ (s, 1H, NH-pyrazole), $\delta 4.89$ (s, 2H, NH₂), $\delta 2.55$ (s, 3H, CH₃); ¹³C-NMR: $\delta 160.61(\text{Pyrazole}), \delta 159.0(\text{Pyrazole}), \delta 160.5$ (C-3), $\delta 147.3$ (C-8), $\delta 136.0$ (C-5), $\delta 132.4$ (C-1'), $\delta 131.8$ (C-3'), $\delta 130.2$ (C-5'), $\delta 129.4$ (C-4'), $\delta 125.6$ (C-7), $\delta 125.9$ (C-2'), $\delta 123.6$ (C-6'), $\delta 121.1$ (C-9), $\delta 115.3$ (C-6), $\delta 110.8$ (C-4), $\delta 98.3$ (Pyrazole), $\delta 20.5$ (CH₃); MS: m/z 291, 274, 147, 143.

Following the above procedure, other 3-methyl-5-(3-aryl-1*H*-pyrazol-5-yl)-7-amine-1,2-benzisoxazoles (7b-j) were prepared. The characterization data of these compounds are summarised in Table-1.

	Characterizatio	n uata or 5-methyr-5	pyrazor-5-yi)-/-anime-1,2-denzisoxazores (/a-j)					
Comp	R	Molecular formula	Mol. Wt.	MP C	Yield (%)	Found (Calculated) %		
						С	Н	Ν
7a	C ₆ H ₅	$C_{17}H_{14}N_4O$	290.3	126	63	70.33 (72.12)	4.86 (4.90)	19.30 (19.05)
7b	4-ClC ₆ H ₄	C ₁₇ H ₁₃ ClN ₄ O	334.7	110	68	62.87 (63.40)	4.03 (4.21)	17.25 (18.30)
7c	2-NO ₂ C ₆ H ₄	$C_{17}H_{13}N_5O_3$	335.3	122	65	60.89 (61.80)	3.91 (4.10)	20.89 (22.30)
7d	$4-NO_2C_6H_4$	$C_{17}H_{13}N_5O_3$	335.3	112	70	60.89 (63.05)	3.91 (4.00)	20.89 (19.69)
7e	4-OHC ₆ H ₄	$C_{17}H_{14}N_4O_2$	306.3	128	67	66.66 (69.78)	4.61 (4.65)	18.29 (19.57)
7f	2-OHC ₆ H ₄	$C_{17}H_{14}N_4O_2$	306.3	133	55	66.66 (67.21)	4.61 (4.60)	18.29 (17.98)
7g	2-C ₄ H ₃ O	$C_{15}H_{12}N_4O_2$	280.2	166	58	64.28 (63.13)	4.32 (4.56)	19.99 (19.20)
7h	2-CH ₃ OC ₆ H ₄	$C_{18}H_{16}N_4O_2$	320.3	101	56	67.49 (69.56)	5.03 (5.32)	17.49 (17.50)
7i	4-CH ₃ OC ₆ H ₄	$C_{18}H_{16}N_4O_2$	320.3	98	48	67.49 (66.98)	5.03 (4.90)	17.49 (19.82)
7j	6-CH ₃ OC ₆ H ₄	$C_{18}H_{16}N_4O_2$	320.3	109	62	67.49 (70.26)	5.03 (5.10)	17.49 (16.36)

Table-1 Characterization data of 3-methyl-5-(3-aryl-1H- pyrazol-5-yl)-7-amine-1,2-benzisoxazoles (7a-i)

Synthesis of 3-methyl-5-(3-phenyl-1*H*-pyrazol-5-yl)-7-amine-(β -D-glucopyranosyl)-1,2-benzisoxazole (9a). It was prepared from 3-methyl-5-(3-phenyl-1*H*-pyrazol-5-yl)-7-amine-1,2benzisoxazole (2.90g, 0.01M) refluxed with tetra-*O*-acetyl glucuropyranosyl bromide (TAGBr) (3.0g, 0.01M) in presence of tetra butyl ammonium bromide (PTC) using dichloromethane as a solvent. The deprotection of above obtained compound 3methyl-5-(3-phenyl-1*H*-pyrazol-5-yl)-7-amine-(β -D-2,3,4,6-

tetra – O - acetyl glucopyranosyl)-1,2-benzisoxazole was done by sodium methoxide in methanol and filtered from ion exchange resin (Amberlite IR 120, H⁺, cation exchanger) to get target molecules.

IR: v_{max} cm⁻¹: 3366 (str.OH), 3143 (N-H), 2929 (Ar-H str), 1634(C=N)⁴¹. ¹H-NMR: $\delta 8.38$ -7.03 (m, 7H, Ar-H), $\delta 6.93$ (s, 1H, Pyrazole), $\delta 4.51$ -4.47 (m, 1H in glucose), $\delta 4.65$ (s, 1H, NH), $\delta 3.81$ -2.70 (6H, glucose), $\delta 2.55$ (s, 3H, CH₃); ¹³C-NMR: $\delta 152.0$ (Pyrazole), $\delta 151.3$ (Pyrazole), $\delta 156.7$ (C-3), $\delta 149.8$ (C-8), $\delta 131.3$ (C-5), $\delta 130.2$ (C-1'), $\delta 129.1$ (C-3'), $\delta 127.9$ (C-5'), $\delta 125.6$ (C-4'), $\delta 126.2$ (C-7), $\delta 124.7$ (C-2'), $\delta 124.9$ (C-6'), $\delta 123.7$ (C-9), $\delta 112.2$ (C-6), $\delta 110.5$ (C-4), $\delta 99.5$ (Pyrazole), $\delta 81.3$ (glucose C-1), $\delta 73.9$ (glucose C-5), $\delta 72.3$ (glucose C-3), $\delta 71.6$ (glucose C-4), $\delta 69.4$ (glucose C-2), $\delta 63.6$ (glucose C-6), $\delta 18.4$ (CH₃)⁴¹ MS: m/z 453, 289, 274, 248, 180, 164, 143, 131⁴³.

Following the above procedure, other *N*-glucosides 3-methyl-5-(3-aryl-1*H*-pyrazol-5-yl)-7-amine- $(\beta$ -D-glucopyranosyl)-1,2-benzisoxazoles (9b-j) were prepared. The characterization data of these compounds are summarized in Table-2.

Polarographic studies: Polarographic studies of 3-methyl-5-(3-phenyl-1*H*-pyrazol-5-yl)-7-amine-1,2-benzisoxazole and 3-methyl-5-(3-phenyl-1*H*-pyrazol-5-yl)-7-amine-(β-D-

glucopyranosyl) -1,2-benzisoxazole were carried out using Elico CL-362 polarograph based on microprocessor operation. The electrode system consisted of dropping mercury electrode as working electrode, platinum wire as auxiliary electrode and saturated calomel electrode as reference electrode. The supporting electrolyte used was 0.1 M KCl solution.

The supporting electrolyte solution was deareated with nitrogen for 15 minutes and polarograms were recorded in DC and DPP modes. To this solution, various concentrations of ethanolic solutions of 3-methyl-5-(3-phenyl-1*H*-pyrazol-5-yl)-7-amine-1,2-benzisoxazole were added and polarograms were recorded for each addition.

The DC polarogram shows a distinct polarographic wave with half wave potential ($E_{1/2}$) -1.700V which matches with the literature value for heterocyclic compounds such as pyrazole group⁴². The differential pulse polarogram shows a distinct peak with peak potential -1.650V.

The supporting electrolyte solution was deareated with nitrogen for 15 minutes and polarograms were recorded in DC and DPP modes. To this solution, various concentrations of ethanolic solutions of 3-methyl-5-(3-phenyl-1*H*-pyrazol-5-yl)-7-amine-(β -D-glucopyranosyl)-1,2-benzisoxazole were added and polarograms were recorded for each addition.

Comm	D	Malaanlan fammala	M-1 XV4	Found (Calculated) %			
Сотр	K	Molecular formula		С	Н	Ν	
9a	C ₆ H ₅	$C_{23}H_{24}N_4O_6$	452.4	61.05 (61.68)	5.35 (5.56)	12.38 (13.00)	
9b	$4-ClC_6H_4$	$C_{23}H_{23}ClN_4O_6$	486.9	56.74 (58.32)	4.76 (4.66)	11.51 (12.30)	
9c	$2-NO_2C_6H_4$	$C_{23}H_{23}N_5O_8$	497.4	55.53 (56.80)	4.66 (4.45)	14.08 (14.96)	
9d	$4-NO_2C_6H_4$	$C_{23}H_{23}N_5O_8$	497.4	55.53 (54.20)	4.66 (4.40)	14.08 (13.90)	
9e	4-OHC ₆ H ₄	$C_{23}H_{24}N_4O_7$	468.4	58.97 (59.30)	5.16 (5.33)	11.96 (12.60)	
9f	2-OHC ₆ H ₄	$C_{23}H_{24}N_4O_7$	468.4	58.97 (60.20)	5.16 (4.99)	11.96 (11.48)	
9g	2-C ₄ H ₃ O	$C_{21}H_{22}N_4O_7$	442.1	57.01 (56.85)	5.01 (5.00)	12.06 (12.82)	
9h	$2-CH_3OC_6H_4$	$C_{24}H_{26}N_4O_7$	482.4	59.74 (60.58)	5.43 (5.95)	11.61 (11.56)	
9i	$4-CH_3OC_6H_4$	$C_{24}H_{26}N_4O_7$	482.4	59.74 (62.10)	5.43 (5.48)	11.61 (10.90)	
9j	6-CH ₃ OC ₆ H ₄	$C_{24}H_{26}N_4O_7$	482.4	59.74 (60.25)	5.43 (6.36)	11.61 (12.10)	

 Table-2

 Characterization data of 3-methyl-5-(3'-aryl-1H- pyrazol-5-yl)-7-amine-(B-D- glucopyranosyl)-1.2-benzisoxazoles (9a-i)

The DC polarogram shows a distinct polarographic wave with half wave potential $(E_{1/2})$ -1.600V which matches with the literature value for sugar group. The differential pulse polarogram shows a distinct peak with peak potential -1.550V⁴².

Results and Discussion

2,4-Diacetyl phenol (1) was synthesised as per reported work in the literature and the structure was confirmed by IR spectrum shows absorption band at 3353 cm⁻¹, which indicates the presence of phenolic -OH group and two peaks shown in the range of 1670 cm⁻¹ and 1641 cm⁻¹, it proven two acetyl group in aforesaid compound. The ¹HNMR spectra showed phenolic proton at δ 12.69 ppm and the molecular mass of compound was confirmed by ion peak at m/z 179.2. The oximinoacetyl-4-acetyl phenol (2) was prepared by the reaction with hydroxylamine hydrochloride and reflux for 1hr in ethanol and water⁴³. The obtained product (2) are refluxed with DMF in presence of acetic anhydride afforded 3-methyl-5-acetyl-1,2-benzisoxazole (3). In IR and ¹HNMR studies it is observed that the disappearance of phenolic -OH group also in ¹³CNMR spectra observed the peak at $\delta 168.66$ ppm and $\delta 110.10$ ppm it confirmed the cyclization and formation of compound (3). Nitration of (3) with nitrating mixture gives 3-methyl-5-acetyl-7-nitro-1,2-benzisoxazole⁴⁴ (4) which on refluxed with reducing mixture tin metal granules and conc. hydrochloric acid to yield reduced product 3-methyl-5-acetyl-7-amine-1,2-benzisoxazole⁴⁵ (5). The obtained compound 5 was confirmed by IR spectra and shown two peaks at 3359 cm⁻¹ and 3253 cm⁻¹, ¹HNMR spectra indicates the peak of two protons at $\delta 4.24$ ppm and MS shows molecular ion peak at m/z 190.

The compounds 3-methyl-5-(3-aryl prop-2-enoyl)-7-amine-1,2benzisoxazoles (6a-j) are prepared by the interaction of 5 with different aromatic and heterocyclic aldehydes using suitable solvent⁴⁶. In IR spectrum the absorption band observed at 1734 cm^{-1} for >C=O group in chalcone. In ¹³CNMR spectra two peaks observed at δ 141ppm and δ 123 ppm for ethylenic (-CH) and for >C=O the peak appears at δ 198 ppm. The reaction of 3-methyl-5-(3'-aryl prop-2'-enoyl)-7-amine-1,2-benzisoxazoles (6a-j) with hydrazine hydrate in alcoholic KOH obtained 3-methyl-5-(3aryl-1*H*-pyrazol-5-yl)-7-amine-1,2-benzisoxazoles⁴⁶ (7a-j). Mass spectra show the molecular ion peak at m/z 291. The 3methyl-5-(3'-aryl-1H-pyrazol-5'-yl)-7-amine-(β-D-2, 3, 4, 6tetra-O-acetyl glucopyranosyl)-1,2-benzisoxazoles (8a-j) have been prepared by Glucosylation of 3-methyl-5-(3'-aryl-1Hpyrazol-5'-yl)-7-amine-1,2-benzisoxazoles with tetra-O-acetyl glucuropyranosyl bromide using PTC and dichloromethane as a solvent. All the synthesized compounds were deprotected by Sodium methoxide in methanol to obtained target molecules 3methyl-5-(3'-aryl-1H-pyrazol-5'-yl)-7-amine-(β-D-

glucopyranosyl)-1,2-benzisoxazoles⁴⁷ (9a-j). The IR spectra of compound show strong band in the range of 3366 cm⁻¹ due to glucosyl –OH. The ¹HNMR spectra show a multiplet due to the glucosyl ring protons in the ranges of δ 3.81-2.70 ppm and the doublet of anomeric proton of the glucose moiety within the

region of δ 4.51-4.47 ppm. The ¹³CNMR spectra show the signal for β -anomeric carbon is observed at δ 81.3 ppm.

Antimicrobial activity: The antifungal screening of compounds 9a-9j were carried out against two fungi viz., Candida albicans and Aspergillus niger adopting the disc diffusion method. The comparison of results was done by using clotrimazole as a standard. The compounds 9b, 9c, 9g and 9h were active and 9a, 9d, 9e, 9f, 9i and 9j were moderately active against A. niger. The compounds 9a-9e, 9h and 9i were active and 9f, 9g and 9j was less active against fungi C. albicans at 800µg/mL concentration. Similarly, the compounds 9a-9j was screened for their antibacterial activity against Escherichia coli and Staphylococcus aureus by disc diffusion method. The standard Ciprofloxacin was used for the comparison of results. The screening result showed the entire compound active against both the bacteria tested at 800µg/mL concentration. Compounds 9b, 9e, 9h and 9j were active and 9a, 9c, 9d, 9f and 9i showed moderately active against bacteria E. coli and 9a, 9b, 9d, 9e, 9i and 9j were active and 9c, 9f, 9g and 9h showed less activity against bacteria S. aureus.

Conclusion

In this article, we have synthesized a new series of 1,2benzisoxazoles and their derivatives like chalcones, pyrazoles, amines and their *N*-glucosides and evaluated for their antimicrobial activities. The compounds 9a-j was screened for anti-bacterial and anti-fungal activities. Compounds 9a-e, 9g, 9h and 9i were active against fungi while 9a, 9b, 9d, 9e, 9i and 9j was active against bacteria.

Thus novel benzisoxazoles derivatives can be incorporated to the family of bioactive heterocyclic compounds.

Acknowledgements

The authors (RJ and YP) wish to express their sincere thanks to University Grant Commission (UGC) and Head, Department of Chemistry, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur. Author (RW) is thankful to Principal, Jawaharlal Nehru College, Wadi, Nagpur.

References

- 1. Czarnik A.W. (1996). Top 20 ethical pharmaceuticals prescribed in the USA in 1994, 17 are heterocyclic compounds, *Acc. Chem. Res.*, 29, 112.
- 2. Meth-Cohn O. (1984). Reviews of several applications of Heterocyclic Compounds. Comprehensive Heterocyclic Chemistry, Vol 1, ed., Pergamon Press, Oxford.
- **3.** Chen Q., Zhu X.L., Jiang L.L. and Yang G.F., (2008). Synthesis, antifungal activity and CoMFA analysis of novel 1,2,4-triazolo[1,5-*a*]pyrimidine derivatives. *Eur. J. Med. Chem.*, 43(3), 595-603.



Scheme-1 Synthesis of 3-Methyl-5-acetyl-1,2-benzisoxazole



Scheme-2

Synthesis of 3-methyl-5-(3'aryl-1*H*- pyrazol-5-yl)-7-amine-(β-D-glucopyranosyl)- 1,2-Benzisoxazoles

- Srinivas K., Srinivas U. and Harikishore K. (2006).
 Synthesis and antibacterial activity of various substituted s-triazines. *Eur. J. Med. Chem.*, 41 (11), 1240-1246.
- Starcevic K., Kralj M., Ester K. and Sabol I., (2007). Synthesis, antiviral and antitumor activity of 2- 7. substituted-5-amidino-benzimidazoles. *Bioorg. Med. Chem.*, 15, 4419-4426.
- Chandra T., Garg N., Suman L. and Saxena S.S., (2010). Synthesis of substituted acridinyl pyrazoline derivatives and their evaluation for anti-inflammatory activity. *Eur. J. Med. Chem.*, 45, 1772-1776.
- Zhao W.G., Chen S.H., Li Z.M. and Han Y.F. (2001). Synthesis of Pyrazolyl-heterocycles and Their Fungicidal Activities. *Chin. J. Chem.*, 22, 939-942.

- **8.** Stanton H.L.K., Gambari R., Chung H.C., Johny C.O.T., Filly C. and Albert S.C.C. (2008). Synthesis and anticancer activity of benzothiazole containing phthalimide on human carcinoma cell lines *Bioorg. Med. Chem.*, 16, 3626-3631.
- **9.** Ramla M.M., Omar M.A. and Tokuda H. (2007). Synthesis and inhibitory activity of new benzimidazoles derivatives against Burkitt's lymphoma promotion. *Bioorg. Med. Chem.*, 15, 6489-6496.
- **10.** Kalirajan R., Sivakumar S.U., Jubie S., Gowramma B. and Suresh B. (2009). Synthesis and Biological evaluation of some heterocyclic derivatives of Chalcones. *Int. J. ChemTech.*, *Res.*, 1(1), 27-34.
- **11.** Aitawade M., Sambavekar P.P. and Anbhule P.V. (2014). Evaluation of insecticidal activity of some benzofused heterocycles against different insect pests. *Ind. J. Chem.*, 53B, 754-762.
- **12.** Eicher T and Hauptmann S. (2003). *Edition IInd, 'The Chemistry of Heterocycles: Structure, Reactions, Syntheses, and Applications', Wiley-VCH, ISBN* 3527307206.
- 13. Chauhan A., Sharma P.K. and Kaushik N. (2011). Pyrazole: A Versatile Moiety. *Int. J. of ChemTech Res.*, 3, 11-17.
- 14. Kumar R., Kumar A., Jain S. and Kaushik D. (2011). Synthesis, antibacterial evaluation and QSAR studies of 7-[4-(5-aryl-1,3,4-oxadiazole-2-yl)piperazinyl] quinolone derivatives. *Eur. J. Med. Chem.*, 46, 3543-3550.
- **15.** Jain N., Pathak D.P., Mishra P. and Jain S. (2013). Antifungal activity of some 2-(5-aryl-1, 3, 4-oxadiazol-2yl thio) acetic acid. *Der Pharm. lett.*, 5(3), 415-418.
- **16.** Holla S., Prasanna C.S., Poojary B. and Rao K.S. (2004). Synthesis and insecticidal activity of some 1,3,4oxidiazoles derived from 2-chloropyridine-5-acetic acid. *Ind. J. Chem.*, 43B, 864-868.
- 17. Aboraja S., Abdel-Rahman H.M. and Mahfouz N.M. (2006). Novel 5-(2-hydroxyphenyl)-3-substituted-2,3-dihydro-1,3,4-xadiazole-2-thione derivatives: Promising anticancer agents. *Bioorg. med. Chem.*, 14, 1236-1246.
- Gudipati R., Anreddy R.N.R. and Manda S. (2011). Synthesis, characterization and anticancer activity of certain 3-{4-(5-mercapto-1,3,4-oxadiazole-2yl)phenylimino}indolin-2-one derivatives. *Saudi Pharm.*, *J.*, 19, 153-158.
- **19.** Cocconcelli G., Diodato E. and Caricasole A. (2008). Aryl azoles with neuroprotective activity-Parallel synthesis and attempts at target identification *Bioorg. Med. Chem.*, 16, 2043-2052.
- **20.** Sharma A., Gupta S.P., Jain S. and Garg G. (2011). Synthesis and biological evaluation of 3-substituted-1,2benzisoxazole derivatives for antimicrobial activity. *Der.*

Phama. Chemica, 3(3), 253-264.

- **21.** Thakar K.A. and Bhawal B.M. (1978). Synthesis and antimicrobial screening of amino-1,2-binzisoxazoles and sulphanilamido-1,2-benzisoxazoles. *Curr. Sci.*, 47, 950-952.
- **22.** Shastri R.A. and Varudkar J.S. (2009). Synthesis and antimicrobial screening of 3-propene-1,2-binzisoxazoles. *Ind. J. Chem.*, 48B, 1156-1160.
- **23.** Dubrovskiy A.V. and Lorak R.C. (2010). Synthesis of Benzisoxazoles by the [3+2] Cycloaddition of *in situ* Generated Nitrile Oxides and Arynes. *Org. Lett.*, 12 (6), 1180-1183.
- 24. Uno H., Kurokawa M., Masada Y. and Mishimura H. (1979). Studies on 3-Substituted 1,2-Benzisoxazole Derivatives. 6. Syntheses of 3-(Sulfamoylmethyl)-1,2-benzisoxazole Derivatives and Their Anticonvulsant Activities. J. Med. Chem., 22, 180-183.
- **25.** Villalobes A. and Blake J.A. (1994). Novel Benzisoxazole Derivatives as Potent and Selective Inhibitors of Acetylcholinesterase. *J. Med. Chem.*, 37, 2721-2734.
- **26.** Strupczewski J.T., Bordeau K.J., Chiang Y. and Glamkowski E.J. (1995). 3-[(Aryloxy)alkyllpiperidinyl]-1,2-Benzisoxazole as Dd5-HT2 Antagonists with Potential Atypical Antipsychotic Activity: Antipsychotic Profile of Iloperidone (HP 873). *J. Med. Chem.*, 38 (7), 1119-1131.
- 27. Roman G., Comanita E. and Comanita B. (2002). Synthesis and reactivity of Mannich bases. Part 15: Synthesis of 3-(2-(1-pyrazolyl)ethyl)-1,2-benzisoxazoles. *Tetrahedron*, 58, 1617-1622.
- **28.** Priya B.S., Basappa S., Swamy N. (2005). Synthesis and characterization of novel 6-fluoro-4-piperidinyl-1,2-benzisoxazole amides and 6-fluoro-chroman-2-carboxamides: antimicrobial studies. *Bioorg. and Med. Chem.*, 13, 2623-2628.
- **29.** De Vincenzo R, Ferlini C, Distefano M, Gaggini C, Riva A, Bombardelli E, Morazzoni P, Valenti P, Belluti F, Ranelletti FO and Mancuso S. (2000). In vitro evaluation of newly developed chalcone analogues in human cancer cells. *Cancer Chemother Pharmacol.* 46, 305–312.
- **30.** Bhat BA, Dhar KL, Puri SC, Saxena AK, Shanmugavel M and Qazi GN. (2005). Synthesis and biological evaluation of Chalcones and their derived Pyrazoles as potential cytotoxic agents. *Bioorg Med Chem Lett.*, 15, 3177–3180.
- **31.** Binder D., Noe C.R., Holzer W. and Rosenwirth B. (1985). Thiophene analog antiviral Chalcone. *Arch. Pharm.*, 318, 48-59.
- **32.** Kumar D., Kumar N.M., Akamatsu K., Kusaka E., Harada H. and Ito T. (2010). Synthesis and biological

evaluation of indolyl chalcones as antitumor agents. *Bioorg. Med. Chem. Lett.*, 20, 3916-3919.

- **33.** Nowakowska Z.A. (2007). A review of anti-infective and anti-inflammatory chalcones. *Eur. J. Med. Chem.* 42, 125-137.
- 34. Larsen M., Kromann H. and Nielsen S.F. (2005). Conformationally restricted anti plasmodial chalcones. *Bioorg. Med. Chem, Lett.*, 15, 4858-4861.
- **35.** Suvitha S., Siddig I.A. (2012). Synthesis of Chalcones with Anticancer Activities. *Molecules*, 17, 6179-6195.
- **36.** Venkatachalam H., Nayak Y. and Jayashree B.S. (2012). Evaluation of the Antioxidant Activity of Novel Synthetic Chalcones and Flavonols. *Int. J. Chemical Engineering and Applications*, 3(3), 216-219.
- **37.** Ingle V.N., Kharche S.T. and Upadhyay U.G. (2005). Glucosylation of 4-hydroxychalcones using glucosyl donor. *Ind. J. Chem.*, Vol. 44B, 801-805.
- **38.** Romeo A., Diaz-Mauino T., Gabius H.J. (2000). Medicinal Chemistry Based on the Sugar Code: Fundamentals of Lectinology and Experimental Strategies with Lectins as Targets. *Cur. Med Chem.*, 7, 389-416.
- **39.** Kalirajan R., Shivakumar S.U. (2009). Synthesis and Biological evaluation of some heterocyclic derivatives of Chalcones. *Int. J. ChemTech Res.*, 1(1), 27-34.

- **40.** Umare V.D., Ingle V.N. and Wanare R.K. (2009). Synthesis of 2-Substituted-6-Nitro-N-1-β-D-Glucopyranosyl Benzimidazoles. *Int. J. ChemTech Res.*, 1 (2), 314-317.
- **41.** Silverstein R.M., Webster F.X. and Kiemle D.J. (2005). *Spectroscopic Identification of Organic Compounds*, 7th *edition;* Wiley New York, Chapter 3.
- **42.** Kapoor R.C. and Aggarwal B.S. (1991). *Principles of Polarography*, Wiley Eastern Limited, 1257, 96-115.
- **43.** Villalobes A. and Blake J.A. (1994). Novel Benzisoxazole Derivatives as Potent and Selective Inhibitors of Acetylcholinesterase. *J. Med. Chem.*, 37, 2721-2734.
- **44.** Patent (2007). US2007/0072867A1.
- **45.** Jones A.G. (1975). The Selective Reduction of Meta-(and Para-) Nitroacetophenone. *J. Chem. Edu.*, 52(10), 668-669.
- **46.** Wanare R.K. (2011). Synthesis of new β-D-glucuronides: β-D-glucuronosyl-5-(3-aryl-1*H*-pyrazol-5-yl)-1,2benzisoxazole-3-carboxylates. *J. Chem. Pharm. Res.*, 3(5), 136-144.
- 47. Ingle V.N. and Wanare R.K. (2007). *Ph.D. Thesis, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur.*